Evofem Biosciences Amends Convertible Note Financing Terms

Evofem Biosciences ( (EVFM) ) has provided an announcement.

On April 10, 2026, Evofem Biosciences, Inc. and funds affiliated with Adjuvant Global Health Technology Fund entered into a fourth amendment to their existing Securities Purchase Agreement governing certain convertible promissory notes. This amendment revises the maturity terms so that the notes become due on the earlier of six months after April 10, 2026, a change of control at Adjuvant’s election, or acceleration under specified default provisions, and it restricts Evofem from prepaying the notes within six months of the effective date without Adjuvant’s prior written consent, underscoring Adjuvant’s control over repayment timing and the company’s continued dependence on structured financing.

Spark’s Take on EVFM Stock

According to Spark, TipRanks’ AI Analyst, EVFM is a Neutral.

The score is held down primarily by weak financial performance (zero reported 2025 revenue, ongoing cash burn, and negative equity with meaningful leverage). Valuation appears optically cheap (low P/E) but is less reliable given earnings quality concerns, while a positive corporate update on operating profitability provides some offset. Technical data is insufficient, so it does not materially support the score.

To see Spark’s full report on EVFM stock, click here.

More about Evofem Biosciences

Evofem Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing women’s sexual and reproductive health products. The company operates in the healthcare sector, with a business model that relies on external financing to support its product pipeline and ongoing operations in this specialized therapeutic area.

Technical Sentiment Signal: Sell

Current Market Cap: $1.18M

For a thorough assessment of EVFM stock, go to TipRanks’ Stock Analysis page.